» Articles » PMID: 30308977

Classification of Cells in CTC-Enriched Samples by Advanced Image Analysis

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2018 Oct 13
PMID 30308977
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

In the CellSearch system, blood is immunomagnetically enriched for epithelial cell adhesion molecule (EpCAM) expression and cells are stained with the nucleic acid dye 4'6-diamidino-2-phenylindole (DAPI), Cytokeratin-PE (CK), and CD45-APC. Only DAPI+/CK+ objects are presented to the operator to identify circulating tumor cells (CTC) and the identity of all other cells and potential undetected CTC remains unrevealed. Here, we used the open source imaging program Automatic CTC Classification, Enumeration and PhenoTyping (ACCEPT) to analyze all DAPI+ nuclei in EpCAM-enriched blood samples obtained from 192 metastatic non-small cell lung cancer (NSCLC) patients and 162 controls. Significantly larger numbers of nuclei were detected in 300 patient samples with an average and standard deviation of 73,570 ± 74,948, as compared to 359 control samples with an average and standard deviation of 4191 ± 4463 ( < 0.001). In patients, only 18% ± 21% and in controls 23% ± 15% of the nuclei were identified as leukocytes or CTC. Adding CD16-PerCP for granulocyte staining, the use of an LED as the light source for CD45-APC excitation and plasma membrane staining obtained with wheat germ agglutinin significantly improved the classification of EpCAM-enriched cells, resulting in the identification of 94% ± 5% of the cells. However, especially in patients, the origin of the unidentified cells remains unknown. Further studies are needed to determine if undetected EpCAM+/DAPI+/CK-/CD45- CTC is present among these cells.

Citing Articles

Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors.

Magri V, De Renzi G, Marino L, De Meo M, Siringo M, Gelibter A Int J Mol Sci. 2024; 25(7).

PMID: 38612563 PMC: 11011814. DOI: 10.3390/ijms25073752.


Ultra high content analyses of circulating and tumor associated hybrid cells reveal phenotypic heterogeneity.

Whalen R, Anderson A, Jones J, Sims Z, Chang Y, Nederlof M Sci Rep. 2024; 14(1):7350.

PMID: 38538742 PMC: 10973471. DOI: 10.1038/s41598-024-57381-8.


Liquid Biopsy in Bladder Cancer.

Cui Y, Cao M Methods Mol Biol. 2023; 2695:111-120.

PMID: 37450114 DOI: 10.1007/978-1-0716-3346-5_7.


Detection and Characterization of Circulating Tumor Cells Using Imaging Flow Cytometry-A Perspective Study.

Muchlinska A, Smentoch J, Zaczek A, Bednarz-Knoll N Cancers (Basel). 2022; 14(17).

PMID: 36077716 PMC: 9454939. DOI: 10.3390/cancers14174178.


Circulating Cells with Macrophage-like Characteristics in Cancer: The Importance of Circulating Neoplastic-Immune Hybrid Cells in Cancer.

Sutton T, Patel R, Anderson A, Bowden S, Whalen R, Giske N Cancers (Basel). 2022; 14(16).

PMID: 36010865 PMC: 9405966. DOI: 10.3390/cancers14163871.


References
1.
Racila E, Euhus D, Weiss A, Rao C, McConnell J, Terstappen L . Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A. 1998; 95(8):4589-94. PMC: 22534. DOI: 10.1073/pnas.95.8.4589. View

2.
Kallergi G, Papadaki M, Politaki E, Mavroudis D, Georgoulias V, Agelaki S . Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011; 13(3):R59. PMC: 3218948. DOI: 10.1186/bcr2896. View

3.
Jamur M, Oliver C . Permeabilization of cell membranes. Methods Mol Biol. 2009; 588:63-6. DOI: 10.1007/978-1-59745-324-0_9. View

4.
de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

5.
Krebs M, Hou J, Sloane R, Lancashire L, Priest L, Nonaka D . Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2011; 7(2):306-15. DOI: 10.1097/JTO.0b013e31823c5c16. View